- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03629379
Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions (STRAUSS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The investigators will prospectively include patients with Crohn's disease (CD) or ulcerative colitis (UC), who develop psoriasiform skin lesions (including psoriasiform eczema, psoriasis guttata, psoriasis inversa and pustulosis) under therapy with anti-TNF and refractory to at least 12 weeks of topical therapy. Since no scoring systems are available to describe (the severity of) anti-TNF induced skin lesions, the lesions will be followed up at different time points using 3 different methods. First, the Dermatology Life Quality Index (DLQI), which is a standardised questionnaire that is used in routine clinical practice to assess the impact of any type of skin lesion on the quality of life of the patient. Next a global visual analogue scale (VAS) to be filled out by the expert dermatologist based on the general appearance of the skin lesions, and finally a self-designed physician global assessment (PGA). Physician global assessment of paradoxical skin lesions will be based on the following:
- Number of body regions that are affected: 1 region (1 point), 2 or 3 regions (2 points) and more than 3 regions (3 points). The 8 regions to consider are: scalp, face, both axilla, groins, genital (including pubis and perineal), trunk (front and back + neck and collar), arms (including hands), legs (including feet)
- Location of skin lesions: face (1 point), palmoplantar (1 point), genital (1 point), flexural (1 point)
- Affected body surface area >10% (3 points)
- Presence of itching (1 point)
- Painful skin lesion (1 point)
- Is the lesion wet including erosions, pustules and maceration (2 points) or dry (0 points)?
- Is the lesion superinfected? Yes (1 point) or No (0 points)
The investigators plan to include 20 patients, namely the first 10 patients who will be switched to ustekinumab (UST, n=10, only available for patients with CD) and the first 10 patients who will be switched to anti-integrin therapy (VDZ, n=10). The latter will be used as a control group to evaluate whether starting ustekinumab or discontinuing anti-TNF leads to improvement of the lesions. Patients will be included through our outpatient clinic or infusion unit. The decision to start ustekinumab or vedolizumab will be based on routine clinical practice, and not be influenced by this study.
At the first evaluation (moment of treatment change), a blood draw (EDTA, serum, PAX gene) will be performed, the clinical CD or UC activity will be calculated by using patient reported outcome (PRO2) and Crohn's Disease Activity Index (CDAI) or Mayo score, and the patient will be asked to fill out a DLQI. Next, the patient will be send to one of two board certified dermatologists. The latter will document the skin lesions, take pictures of all lesions, state the clinical diagnosis and perform two punch biopsies of the affected skin ánd of unaffected skin at the contralateral sight. The dermatologist will also fill out the above mentioned VAS and PGA.
Patients switched to ustekinumab will receive standard induction with intravenous ustekinumab 6mg/kg, followed by subcutaneous ustekinumab 90mg every 8 weeks. Patients switched to vedolizumab will receive standard induction with intravenous vedolizumab 300mg at weeks 0, 2, 6, 10, 14 and every 8 weeks thereafter.
The patients will be re-evaluated 6-8 and 14-16 weeks after change in treatment. At week 6-8, patients will be clinically (including PRO2, CDAI/Mayo, and DLQI) and serologically (blood samples) re-evaluated by one of our three inflammatory bowel disease (IBD) specialists and all lesions will be photographed again. At week 14-16, re-evaluation by a gastroenterologist as well as dermatologist will take place. This will also include a new skin biopsy, but only at the initial site of the skin lesions (not the unaffected contralateral sight) (cfr. Study diagram). Dermatological response will be defined as a drop in VAS with at least 50%.
All blood samples will be analysed at the Translational Research in GastroIntestinal Disorders (TARGID) lab, Catholic University Leuven. One of the baseline skin biopsies will be send for histological examination by a certified pathologist (prof. dr. van den Oord) to obtain a correct histological diagnosis of the lesion. All the other biopsies will be stored in the TARGID-lab, Catholic University Leuven and will be used to perform transcriptomic and proteomic analyses (see further).
First, all patients included will be genetically characterize by using the Infinium Global Screening Array (GSA, Illumina). For the analyses the investigators will collaborate with the Department of Complex Genetics and Genomics Core Leuven. Next, a weighted polygenetic risk score will be calculated for all individuals. By performing a weighted risk score, the effect size and population frequency of the included genetic variants will be taken into account. The latter will be taken from already published genome-wide association studies. Using GSA will also enable the investigators to find new allele. Third, compare protein expression between the different patients groups will be compared by using serum tubes. Protein biomarkers in serum will be compared using the immunology panel (OLINK Proteomics). This panel is a high-throughput, multiplex immunoassay enabling analysis of 92 protein biomarkers across 96 samples simultaneously. The proteins will be analyzed following quality control and excluding markers with >75% missing data. To validate the found biomarkers the Mesoscale platform (Meso Scale Diagnostics) will be used. In addition, differences in gene expression in blood as well as skin biopsies will be compared. For the blood analyses PAX tubes will be used from the investigators' biobank. To extract RNA from PAX tubes the PAXgene Blood RNA Kit (Qiagen) will be used. For RNA extraction from skin biopsies AllPrep DNA/RNA Mini Kit (Qiagen) will be used. After extraction of RNA, next-generation single-end sequencing will be performed in collaboration with the Genomics core facility, Leuven. The high sequencing (4000NGS) platform from Ilumina will be used. Based on this proof of concept study a more limited panel of markers will be developed and evaluate in a confirmation cohort.
It is known that TNF, type I interferon (IFN) and interleukin-17 (IL-17) play an important role in the development of paradoxical psoriasiform skin lesions with the overproduction of IFN being the major driving force.(14, 33) However, the interplay between IL-17 and IFN is not clear. In addition, which immune cells are activated by IFN and through which cytokines is still unknown. To help solve these questions, skin biopsies will be used to further explore the interplay between IFN and other cytokines (IL-17, IL-22 and IL-23) and cells (innate lymphoid cells, ILC3) in patients treated with anti-TNF and how this interplay changes when treatment is changed to anti-IL12/23 therapy or vedolizumab.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Marc Ferrante, MD
- Phone Number: 003216342845
- Email: marc.ferrante@uzleuven.be
Study Contact Backup
- Name: Annick Moens, MD
- Phone Number: 003216340998
- Email: annick.moens@kuleuven.be
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with CD or UC, who develop psoriasiform skin lesions (including psoriasiform eczema, psoriasis guttata, psoriasis inversa and pustulosis) under therapy with anti-TNF and refractory to at least 12 weeks of topical therapy.
- Written informed consent must be obtained and documented.
Exclusion Criteria:
- IBD patients not treated with anti-TNF therapy
- IBD patients with skin lesions under anti-TNF not refractory to topical therapy
- Patients who previously received anti-interleukin 12/23 (IL12/23) or anti-interleukin 23 therapy
- Patients with history of psoriasis prior to initiation of anti-TNF therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: ustekinumab arm
First 10 patients who are switched from anti-TNF to ustekinumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
|
Patients will receive standard dosing of ustekinumab with a single intravenous infusion of about 6mg/kg ustekinumab at week 0, followed by ustekinumab 90mg subcutaneously every 8 weeks.
Other Names:
|
Active Comparator: vedolizumab arm
First 10 patients who are switched from anti-TNF to vedolizumab because of psoriasiform skin lesions refractory to 12 weeks of topical therapy.
|
Patients will receive standard dosing of vedolizumab 300mg at weeks 0, 2, 6, and 14.
Patients with Crohn's disease could receive an extra infusion at week 10.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Transcriptomic features
Time Frame: 3 years
|
Transcriptomic profile will be established by analysis of the expression of the mRNAs by using Next Generation Sequencing.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proteomic features
Time Frame: 3 years
|
Proteomic profile will be established by using a proximity extension assay from OLINK
|
3 years
|
Mechanistic changes in psoriasiform skin lesions
Time Frame: 3 years
|
Physiological changes that occur with respect to cell types and cytokines will be investigated using immunohistochemistry and cell sorting
|
3 years
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Cleynen I, Van Moerkercke W, Billiet T, Vandecandelaere P, Vande Casteele N, Breynaert C, Ballet V, Ferrante M, Noman M, Assche GV, Rutgeerts P, van den Oord JJ, Gils A, Segaert S, Vermeire S. Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study. Ann Intern Med. 2016 Jan 5;164(1):10-22. doi: 10.7326/M15-0729. Epub 2015 Dec 8.
- Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012 Sep;9(9):496-503. doi: 10.1038/nrgastro.2012.125. Epub 2012 Jul 3.
- Tillack C, Ehmann LM, Friedrich M, Laubender RP, Papay P, Vogelsang H, Stallhofer J, Beigel F, Bedynek A, Wetzke M, Maier H, Koburger M, Wagner J, Glas J, Diegelmann J, Koglin S, Dombrowski Y, Schauber J, Wollenberg A, Brand S. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-gamma-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut. 2014 Apr;63(4):567-77. doi: 10.1136/gutjnl-2012-302853. Epub 2013 Mar 6.
- Grine L, Dejager L, Libert C, Vandenbroucke RE. An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17. Cytokine Growth Factor Rev. 2015 Feb;26(1):25-33. doi: 10.1016/j.cytogfr.2014.10.009. Epub 2014 Oct 31.
- Conrad C, Di Domizio J, Mylonas A, Belkhodja C, Demaria O, Navarini AA, Lapointe AK, French LE, Vernez M, Gilliet M. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018 Jan 2;9(1):25. doi: 10.1038/s41467-017-02466-4.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- S61472
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Diseases
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Icahn School of Medicine at Mount SinaiNorthwestern University; The Cleveland Clinic; University of California, Davis; RxHealt...RecruitingInflammatory Bowel Disease (IBD)United States
-
Nemours Children's ClinicNASPGHAN FoundationCompletedInflammatory Bowel Disease (IBD)United States
-
Hull University Teaching Hospitals NHS TrustWellcome/EPSRC Centre for Interventional and Surgical Sciences, University...RecruitingInflammatory Bowel Disease 1United Kingdom
Clinical Trials on Ustekinumab
-
Janssen Research & Development, LLCCompletedPsoriasisUnited States, Germany, Taiwan, Belgium, Korea, Republic of, Canada, Poland, Hungary, Netherlands
-
Janssen Research & Development, LLCCompletedPrimary Biliary CirrhosisUnited States, Canada
-
Centocor, Inc.CompletedCrohn's DiseaseUnited States, France, United Kingdom, Germany, Spain, Belgium, Israel, Australia, Canada, Netherlands, New Zealand, Austria
-
Samsung Bioepis Co., Ltd.CompletedPsoriasis | Moderate to Severe Plaque PsoriasisCzechia, Estonia, Hungary, Korea, Republic of, Latvia, Lithuania, Poland, Ukraine
-
Jewish General HospitalCompletedType 1 Diabetes MellitusCanada
-
Bioeq GmbHCompletedPlaque PsoriasisPoland, Estonia, Ukraine, Georgia
-
Janssen Research & Development, LLCCompletedPsoriasisFrance, Ukraine, United Kingdom, Germany, Portugal, Canada, Belgium, Russian Federation, Hungary, Sweden
-
Centocor, Inc.Completed
-
Janssen Research & Development, LLCTerminatedLupus Erythematosus, SystemicUnited States, Japan, Korea, Republic of, Canada, Taiwan, Thailand, Germany, China, Serbia, Spain, Portugal, Russian Federation, Poland, Ukraine, Lithuania, South Africa, Hungary, Argentina, Bulgaria, Colombia
-
Janssen Research & Development, LLCWithdrawnLupus Erythematosus, SystemicChina